Brad Heckmann

Company: ASHA therapeutics

Job title: Chief Scientific Officer

Seminars:

Building the Perfect Key – Designing Degraders to Maximize Efficacy & Safety 4:30 pm

• Identifying novel pockets on proteins of interest to design degrader molecules • Optimizing physical chemical properties for more favorable ADME characteristics • Back validation of PRISM with robust efficacy and safety of developed compoundsRead more

day: Conference Day 1

Panel Discussion: Moving from Phenotypic Screening to Target Based Discovery 8:50 am

• Overview of panellist’s platform technologies to identify glues and degraders including scientific or technical hurdles platforms address • How can we combat the diversity in compounds when rationally designing novel candidates? • What features define a protein as ligandable within a target space? • How can we provide systematic and scalable screening panels; the…Read more

day: Conference Day 2